Antibiotic Heteroresistance, Tolerance & Persistence: Mechanisms & Clinical Relevance

The fight against antibiotic resistance is entering a more nuanced phase. Beyond the well-documented issue of bacteria evolving outright resistance to drugs, researchers are increasingly focused on phenomena like heteroresistance and persistence – states where bacteria aren’t necessarily killed by an antibiotic, but survive in a dormant or tolerant state, allowing infections to linger and potentially evolve resistance later. These subtle mechanisms are proving difficult to detect with standard clinical testing, posing a significant challenge to effective treatment.

Understanding Heteroresistance: A Subpopulation Advantage

Bacterial heteroresistance, as defined in a recent review published in Nature Microbiology, describes a situation where a bacterial population isn’t uniformly susceptible to an antibiotic. Instead, a small subpopulation exhibits reduced susceptibility, even while the overall population appears sensitive based on standard minimum inhibitory concentration (MIC) testing. This means that standard lab tests might indicate an antibiotic *should* work, but it fails to eradicate the infection in a patient. The review highlights that this isn’t simply a precursor to full resistance, but a distinct state with its own clinical implications.

The difficulty in detecting heteroresistance stems from the averaging effect of MIC testing. Traditional methods determine the lowest concentration of an antibiotic that inhibits visible growth of a bacterial culture. However, this doesn’t reveal the presence of those less-susceptible subpopulations. As noted in a 2021 study in mBio, colistin heteroresistance, for example, is often undetected using standard methods, potentially leading to inappropriate treatment decisions.

Several mechanisms contribute to heteroresistance. Gene amplification, where bacteria increase the number of copies of genes conferring resistance, is a key driver, as demonstrated by research published in Nature Communications in 2019. Other mechanisms include epigenetic changes and variations in cell physiology. The dynamic nature of these subpopulations – their ability to fluctuate in size and composition – further complicates detection, as highlighted in a 2021 study in Communications Biology.

Persistence: A Temporary State of Dormancy

Distinct from heteroresistance, bacterial persistence is a phenotypic state where a subpopulation of bacteria enters a dormant-like state, becoming tolerant to antibiotics without any genetic changes. These “persister” cells don’t grow, and therefore aren’t killed by antibiotics that target actively growing bacteria. When antibiotic treatment stops, these persisters can “wake up” and re-establish the infection.

The concept of persistence was initially described in 2004 in Science, and subsequent research has revealed that it’s not a random process. A study in PLoS Pathogens in 2020 showed that persistence is regulated by complex signaling pathways. More recently, research published in PNAS in 2019 demonstrated a power-law distribution in the lag time before persisters resume growth, suggesting a highly regulated and non-random process.

Unlike resistance, persistence isn’t inherited by daughter cells. It’s a transient state, but its impact on treatment failure is significant. The presence of persisters can lead to chronic infections and contribute to the development of resistance, as they provide a reservoir for mutations to arise during antibiotic exposure. A 2017 study in Science showed that antibiotic tolerance, closely linked to persistence, can actually *facilitate* the evolution of resistance.

Clinical Implications and the Need for New Approaches

The clinical relevance of both heteroresistance and persistence is becoming increasingly clear. Heteroresistance can lead to treatment failure even when antibiotics appear effective in the lab, while persistence explains why some infections recur after seemingly successful treatment. A 2021 review in Clinical Microbiology Reviews emphasizes the importance of understanding these mechanisms to improve clinical outcomes.

Current diagnostic methods, based on determining MICs (as outlined by the Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing), are often inadequate for detecting these phenomena. MIC testing provides a snapshot of the average susceptibility of a population, masking the presence of resistant subpopulations or dormant persisters. New methods are needed to identify and quantify these subpopulations.

Researchers are exploring several approaches, including single-cell analysis techniques, which allow for the measurement of antibiotic susceptibility at the individual cell level. A 2017 study in PNAS demonstrated a method for rapid antibiotic susceptibility testing using direct single-cell imaging. Other approaches focus on identifying biomarkers associated with persistence or heteroresistance.

Understanding the interplay between persistence, heteroresistance, and the evolution of full resistance is crucial. Research suggests that persistence can increase the likelihood of resistance development by providing a refuge for bacteria to accumulate mutations. A 2019 study in ISME Journal showed that bacterial persistence can actually increase mutation rates, accelerating the evolution of resistance. Bacteria can sometimes compensate for the fitness costs associated with resistance genes, as demonstrated in a 2024 study in Nature Communications, making resistance more sustainable.

Addressing these challenges requires a multi-pronged approach, including the development of new antibiotics, improved diagnostic tools, and strategies to prevent the emergence and spread of resistance. Recognizing the limitations of current susceptibility testing methods and embracing more sophisticated techniques will be essential to combatting the growing threat of antibiotic resistance.